Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis
Launched by MILTON S. HERSHEY MEDICAL CENTER · Jul 6, 2023
Trial Information
Current as of July 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Broadly, synkinesis is a neuromuscular condition in which voluntary muscle contraction causes simultaneous involuntary contraction of other muscle groups e.g. pursing of the lips causes involuntary closure of the eye. It is a common sequelae of facial nerve paralysis with 55% or more of patients reporting synkinetic facial movement. 2 Additionally, patients may develop hyperkinesis due to continual firing of nerves that have aberrantly regenerated, thereby causing decreased movement due to antagonistic muscle hyperactivity, tightness, spasms, and pain. These together significant affect faci...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Over 18 years of age
- • 2. Primary diagnosis of nonflaccid facial paralysis (aberrant regeneration syndrome) and acquired blepharoptosis.
- Exclusion Criteria:
- • 1. Patients under the age of 18
- • 2. Patients on cardiac glycosides
- • 3. Patients on MAO inhibitors
- • 4. Patients with angle closure glaucoma
- • 5. Patients who experience asymmetrical eye opening due to weakness (e.g. lagophthalmos).
About Milton S. Hershey Medical Center
Milton S. Hershey Medical Center, a leading academic medical institution affiliated with Penn State University, is dedicated to advancing healthcare through innovative research and clinical trials. With a strong emphasis on patient-centered care, the center leverages its expertise in various medical fields to conduct rigorous clinical studies aimed at improving treatment outcomes and enhancing the understanding of complex health conditions. The facility is committed to ethical research practices and fostering collaboration among multidisciplinary teams, ensuring that participants receive the highest standard of care while contributing to the advancement of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hershey, Pennsylvania, United States
Patients applied
Trial Officials
Jessyka Lighthall, MD
Principal Investigator
Penn State Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported